Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Phenytoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.96 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.96 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.96 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.96 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.96 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | HTR2A | P28223 | 1/20 | 0.96 |
| ▸ | HRH1 | P35367 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.96 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.96 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.96 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.76 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenytoin SCHEMBL5160618 | 1.00 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL2905858 | 0.98 | CYP2C9 (0.92) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL3440 | 0.98 | CYP2C9 (1.00) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL5499612 | 0.98 | CYP2C9 (1.00) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL2905857 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL1461588 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL28548871 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL10406406 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL2140317 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL29521348 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6471 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120078718-A | Oral brain-targeted nanoemulsion and preparation method and application thereof | 四川大学 | 2025-06-03 | — | — | CN | claimed |
| CN-119977228-A | Application of advanced oxidation system in treatment of pollutants in water body and treatment method of pollutants in water body | 北京师范大学珠海校区 | 2025-05-13 | — | — | CN | claimed |
| CN-119901852-A | Method for synchronously measuring multiple medicinal components in biological sample based on LC-MS/MS technology | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2025-04-29 | — | — | CN | claimed |
| CN-118217403-B | Application of HDAC5 gene in regulation of P-glycoprotein expression in hypoxia state | 中国人民解放军联勤保障部队第九〇四医院 | 2025-04-18 | — | — | CN | claimed |
| CN-119732904-A | Sodium fosphenytoin injection and preparation method thereof | 科诺凯医药科技(四川)有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119707824-A | Method for preparing phenytoin sodium by one-pot method | 四川文理学院 | 2025-03-28 | — | — | CN | claimed |
| CN-119684216-A | Method for preparing phenytoin sodium | 云鹏医药集团有限公司 | 2025-03-25 | — | — | CN | claimed |
| EP-3551182-B1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B V (NL) | 2025-03-19 | — | — | EP | claimed |
| US-12220442-B2 | Antiepileptic toxin Martentoxin and use thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-02-11 | — | — | US | claimed |
| WO-2025026457-A1 | MODIFIED FLAVONE COMPOUNDS AND USE THEREOF | 苏州格兰科医药科技有限公司 | 2025-02-06 | — | — | WO | claimed |
| US-5071655-A | Pharmaceutical combination for treatment of bone-wasting diseases | BAYLINK DAVID J (US) | 1991-12-10 | — | — | US | claimed |
| EP-0411619-A1 | Formulations of phenytoin sodium for intravenous administration | WARNER-LAMBERT COMPANY (US) | 1991-02-06 | — | — | EP | claimed |
| US-4952402-A | EDIBLE TASTE-MASKED DRUGS; MICROMATRIX ACTIVE MATERIAL COATED WITH NONTOXIC POLYMER; LIQUIDS; TABLETS | ELAN CORPORATION, P.L.C. (IE) | 1990-08-28 | — | — | US | claimed |
| US-4911931-A | Fluorine source and mitogenic hydratoin | BAYLINK DAVID J (US) | 1990-03-27 | — | — | US | claimed |
| WO-1989000856-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF BONE-WASTING DISEASES | OSTEOTECH CORPORATION (US) | 1989-02-09 | — | — | WO | claimed |
| EP-0302714-A2 | Pharmaceutical composition for treatment of bone-wasting diseases | OSTEOTECH CORPORATION (US) | 1989-02-08 | — | — | EP | claimed |
| US-4696814-A | Parenteral phenytoin compositions | WARNER-LAMBERT COMPANY (US) | 1987-09-29 | — | — | US | claimed |
| EP-0212853-A2 | Parenteral phenytoin compositions | WARNER-LAMBERT COMPANY (US) | 1987-03-04 | — | — | EP | claimed |
| US-4642316-A | Parenteral phenytoin preparations | WARNER-LAMBERT COMPANY (US) | 1987-02-10 | — | — | US | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |